| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
Harbin Medisan Pharmaceutical Co. Ltd (SHE: 002900)
002900 Technical Analysis
2
| As on 29th Jan 2026 002900 STOCK Price closed @ 11.87 and we RECOMMEND Sell for LONG-TERM with Stoploss of 12.78 & Strong Buy for SHORT-TERM with Stoploss of 10.13 we also expect STOCK to react on Following IMPORTANT LEVELS. |
002900STOCK Price
| Open | 12.18 | Change | Price | % |
| High | 12.49 | 1 Day | -1.01 | -7.84 |
| Low | 11.61 | 1 Week | -1.08 | -8.34 |
| Close | 11.87 | 1 Month | -0.93 | -7.27 |
| Volume | 10740331 | 1 Year | 1.08 | 10.01 |
| 52 Week High 16.70 | 52 Week Low 9.12 | ||||
SHE China Most Active Stocks
| 000630 | 9.19 | 10.06% |
| 002131 | 9.57 | 9.12% |
| 300058 | 23.40 | 14.93% |
| 002506 | 3.56 | 1.42% |
| 000620 | 3.72 | 0.00% |
| 000725 | 4.45 | -1.77% |
| 002195 | 10.15 | 3.78% |
| 000981 | 4.57 | -3.99% |
| 300017 | 16.80 | 7.76% |
| 002400 | 12.46 | 5.77% |
SHE China Top Gainers Stocks
SHE China Top Losers Stocks
| 002900 Daily Charts |
002900 Intraday Charts |
Whats New @ Bazaartrend |
002900 Free Analysis |
|
|
002900 Important Levels Intraday
| RESISTANCE | 13.57 |
| RESISTANCE | 13.02 |
| RESISTANCE | 12.69 |
| RESISTANCE | 12.35 |
| SUPPORT | 11.39 |
| SUPPORT | 11.05 |
| SUPPORT | 10.72 |
| SUPPORT | 10.17 |
002900 Forecast January 2026
| 4th UP Forecast | 14.59 |
| 3rd UP Forecast | 13.72 |
| 2nd UP Forecast | 13.18 |
| 1st UP Forecast | 12.64 |
| 1st DOWN Forecast | 11.1 |
| 2nd DOWN Forecast | 10.56 |
| 3rd DOWN Forecast | 10.02 |
| 4th DOWN Forecast | 9.15 |
002900 Weekly Forecast
| 4th UP Forecast | 13.14 |
| 3rd UP Forecast | 12.73 |
| 2nd UP Forecast | 12.48 |
| 1st UP Forecast | 12.23 |
| 1st DOWN Forecast | 11.51 |
| 2nd DOWN Forecast | 11.26 |
| 3rd DOWN Forecast | 11.01 |
| 4th DOWN Forecast | 10.60 |
002900 Forecast2026
| 4th UP Forecast | 29.95 |
| 3rd UP Forecast | 24.15 |
| 2nd UP Forecast | 20.57 |
| 1st UP Forecast | 16.98 |
| 1st DOWN Forecast | 6.76 |
| 2nd DOWN Forecast | 3.17 |
| 3rd DOWN Forecast | -0.41 |
| 4th DOWN Forecast | -6.21 |
Harbin Medisan Pharmaceutical Co. Ltd ( SHE China Symbol : 002900 )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
002900 Business Profile
Harbin Medisan Pharmaceutical Co., Ltd. researches, develops, produces, and sells chemical formulations in China. It offers Araxetan, alanyl glutamine, brain protein hydrolyzate, ligustrazine hydrochloride, bone peptide, Yanhuning, glucose, and sodium chloride injections, as well as rice nitrogen tablets, valsartan dispersible tablets, and other drugs for use in the various indications comprising nervous system, cardiovascular and cerebrovascular, musculoskeletal, systemic anti-infective, regulating water, electrolyte and acid-base balance, nutritional supplements, and other medical fields. The company was founded in 1996 and is based in Harbin, China. Address: Limin Development Zone, Harbin, China, 150025
� 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service